In September a special PME supplement took aim at the industry’s challenges in pricing, value and access in the UK, providing practical advice on navigating the HTA process, communicating your value proposition to payers and demonstrating value in the real world.
We looked at the future of England’s Cancer Drugs Fund – increasingly in doubt since the siloed budget for oncology treatments appears set to be integrated into NICE.
Napp Pharmaceuticals provided thoughts on access to innovative medicines and achieving a sustainable NHS – the achievement of both require looking beyond pricing.
When it comes to value we asked how observational data can assist with scaling reimbursement barriers and help inform payer decisions, before tackling the assessment and communication of the value proposition.
Finally there’s guide to navigating the way to a positive HTA and a look at the UK healthcare payer network, which remains as complex as ever.
